Academic Appointments
- Professor of Pharmacology and Robert Sonneborn Professor of Medicine
- Professor of Urologic Sciences (in Urology)
- Professor of Pathology and Cell Biology and of Systems Biology (in the Herbert Irving Comprehensive Cancer Center and the Institute for Cancer Genetics)
- Chair, Department of Molecular Pharmacology and Therapeutics
Dr. Abate-Shen began her independent career as an Assistant Professor at Rutgers Medical School in 1991, where she rose quickly through the ranks, becoming Professor, Chief of the Division of Research in the Department of Medicine, and co-leader of the Prostate Program for The Cancer Institute of New Jersey. In 2007, Dr. Abate-Shen was recruited to the faculty of Columbia University Vagelos College of Physicians and Surgeons as the Michael and Stella Chernow Professor of Urological Oncology, at the Herbert Irving Comprehensive Cancer Center (HICCC), with appointments in the Departments of Urology, Pathology & Cell Biology, Medicine, Systems Biology, and the Institute of Cancer Genetics. In 2008, she was appointed Associate Director at the HICCC, and served as its Interim Director in 2012 as well as in 2017-2018. In 2019, she was appointed as Chair of the Department of Pharmacology, and the Robert Sonneborn Professor of Pharmacology at Columbia University Vagelos College of Physicians and Surgeons
Dr. Abate-Shen is an internationally-recognized leader in genitourinary malignancies. Her innovative studies of genetically-engineered mouse models for these cancers have led to the discovery of new biomarkers for early detection, as well as advances in cancer prevention and treatment. In recognition of her achievements, Dr. Abate-Shen has been the recipient of numerous awards, including a Sinsheimer Scholar Award, an NSF Young Investigator Award, and an American Cancer Society Research Professorship, the first to be awarded at Columbia University Medical Center. She has served on the Board of Scientific Counselors of the National Cancer Institute, as well as on its Blue Ribbon Panel Working Group for the Cancer Moonshot Initiative. Dr. Abate-Shen has served in various leadership roles in the American Association for Cancer Research including a member of its Board of Directors. Dr. Abate-Shen has also participated extensively in national grant review sections including as the chair of the NIH Molecular Oncology Study Section. Recently, she has been elected as a fellow of the American Association for the Advancement of Science.
Dr. Abate-Shen’s research focuses on the molecular mechanisms of cancer development. She has a longstanding commitment to the generation of mouse models of cancer and their effective use for translational research. Her major research interests are in the area of genitourological cancer. Most notably, her laboratory has developed novel models of prostate and bladder cancer, which have been utilized for investigating the molecular basis of the disease as well as preclinical models for evaluating new therapies.
Departments and Divisions
- Department of Molecular Pharmacology and Therapeutics
- Department of Urology
- Department of Pathology & Cell Biology
Centers / Institutes / Programs
- Herbert Irving Comprehensive Cancer Center
Lab Locations
Irving Cancer Research Center
1130 St. Nicholas Avenue
321 3
New York, NY 10032
Research Interests
- Genitourinary cancer development
- Molecular mechanisms of cancer development
NIH Grants
MITOCHONDRIAL AND NUCLEAR FUNCTIONS OF NKX3.1 IN REGULATING OXIDATIVE STRESS IN PROSTATE CANCER (Federal Gov)
Dec 1 2018 - Nov 30 2023
MODELING BLADDER CANCER PATHOGENESIS AND TUMOR EVOLUTION (Federal Gov)
Sep 11 2018 - Aug 31 2023
PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)
Feb 14 2018 - Jan 31 2023
MOLECULAR DETERMINANTS OF PROSTATE CANCER PROGRESSION (Private)
Jan 1 2016 - Dec 31 2021
CENTERS FOR CANCER SYSTEMS THERAPEUTICS (CAST) (Federal Gov)
Aug 8 2016 - Jul 31 2021
TARGETING ERCC2 TO OVERCOME CHEMOTHERAPY RESISTANCE IN METASTATIC BLADDER CANCER (Private)
Jul 1 2019 - Jun 30 2021
THET.J. MARTELL FOUNDATION FOR LEUKEMIA, CANCER AND AIDS RESEARCH (Private)
Jan 1 2015 - Dec 31 2020
INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)
Apr 1 2015 - Sep 30 2020
MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)
Jan 1 2015 - Jun 30 2020
INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)
Apr 1 2015 - Mar 31 2020
MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)
Jan 1 2015 - Dec 31 2019
MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)
Jan 1 2015 - Dec 31 2019
ANALYSIS OF DRUG RESPONSE IN ORGANOIDS AND MOUSE MODELS (Federal Gov)
Jul 1 2016 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
CANCER CENTER SUPPORT GRANT (Federal Gov)
Jul 1 2014 - Jun 30 2019
CHARACTERIZATION OF EPIGENETIC REGULATORY DRIVERS OF PROSTATE CANCER METASTASIS (Federal Gov)
Sep 15 2016 - Sep 14 2018
PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)
Aug 6 2013 - May 31 2018
PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)
Aug 6 2013 - May 31 2018
PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)
Aug 6 2013 - May 31 2018
CHARACTERIZATION OF EPIGENETIC REGULATORY DRIVERS OF PROSTATE CANCER METASTASIS (Federal Gov)
Nov 1 2015 - Oct 31 2017
FUNCTIONAL IDENTIFICATION OF MASTER REGULATORS OF PROSTATE CANCER METASTASIS THROUGH CRISPR/CAS9 SCREENING (Federal Gov)
Jul 1 2015 - Aug 16 2017
EPIGENETIC REGULATION OF BLADDER CANCER PROGRESSION (Private)
Jul 15 2015 - Jul 14 2017
RESEARCH FOR A 5-GENE PANEL (PRO-SCOPE) FOR IMPROVED EARLY DIAGNOSIS OF PROSTATE CANCER (Private)
Mar 6 2015 - Mar 5 2017
MOLECULAR MECHANISMS OF PROSTATE CANCER INITIATION (Federal Gov)
Sep 16 2011 - Feb 28 2017
MOLECULAR DETERMINANTS OF PROSTATE CANCER PROGRESSION (Private)
Jan 1 2012 - Dec 16 2016
NATIONAL CENTER: MULTISCALE ANALYSIS OF GENOMIC AND CELLULAR NETWORKS (MAGNET) (Federal Gov)
Sep 26 2005 - Jul 31 2016
CELL OF ORIGIN OF BLADDER CANCER (Private)
Jul 1 2014 - Jun 30 2016
INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)
Apr 1 2015 - Mar 31 2016
INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)
Apr 1 2015 - Mar 31 2016
ANALYSES OF THE ROLE OF P53 IN ABIRATERONE RESPONSE (Private)
Jul 1 2014 - Nov 14 2014
LEADERSHIP COMPONENT IN CHEMOPREVENTION: MOUSE MODELS OF HUMAN CANCER CONSORTIUM (Federal Gov)
Sep 1 2009 - Aug 31 2014
ELUCIDATION OF CANCER PATHWAYS AND DRUGGABLE TARGETS USING MOUSE MODELS (Federal Gov)
Sep 30 1999 - Jul 31 2014
PRECLINICAL INVESTIGATIONS OF FINASTERIDE IN MOUSE MODELS OF PROSTATE CANCER (Federal Gov)
Jul 1 2012 - May 31 2014
PRE-CLINICAL AND CLINICAL APPROACHES FOR DEVELOPING NEW TREATMENTS FOR CASTRATION-RESISTANT PROSTATE CANCER (Private)
Sep 1 2010 - Aug 31 2013
ASSEMBLY OF A PROSTATE CANCER GENOME-WIDE MOLECULAR INTERACT OME FOR THE IDENTIFICATION OF THE KEY REGULATORY GENES OF MA (Private)
Aug 1 2010 - Jul 31 2013
THEUSE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLA TIN (CGC) IN THE TREATMENT OF HIGH RISK NON-MUSCLE INVASIVE (Private)
Jul 1 2012 - Jun 30 2013
MOLECULAR MECHANISMS OF INVASIVE BLADDER CANCER: ANALYSIS OF ARF FUNCTION IN P53/PTEN (Private)
Jul 1 2011 - Jun 30 2012
NOVEL THERAPEUTIC TARGETS IN INVASIVE BLADDER CANCER (Private)
Jul 1 2011 - Jun 30 2012
MODELING ANDROGEN-INDEPENDENT PROSTATE CANCER IN MUTANT MICE (Federal Gov)
Apr 1 2007 - Jan 31 2012
NEXT-GENERATION MOUSE MODELS OF PROSTATE CANCER PROGRESSION AND METASTASES (Private)
Jul 1 2008 - Jun 30 2011
ANALYSES OF EARLY STAGE PROSTATE CARCINOGENESIS: TARGETING T HE NFKB PATHWAY FOR EARLY INTERVENTION (Private)
Jul 1 2009 - Jun 30 2011
PRECLINICAL TESTING OF MTOR AND AKT INHIBITORS ON A MOUSE MO DEL OF PROSTATE CANCER (Private)
Jun 24 2009 - Jun 23 2011
PRECLINICAL STUDIES OF SIGNALING PATHWAY IN A MUTANT MOUSE M ODEL OF HORMONE-REFRACTORY PROSTATE CANC (Federal Gov)
Jan 28 2008 - Apr 30 2011
ROLE FOR MSX1 IN VERTEBRATE EMBRYOGENSIS (Federal Gov)
Aug 1 1992 - Nov 30 2009
CHEMOPREVENTION OF PROSTATE CANCER IN MUTANT MICE: TARGETING THE ANDROGEN RECEPTOR SIGNALING PATHWAY (Federal Gov)
Dec 2 2007 - Nov 14 2009
Publications
Park, S., Rong, L., Owczarek, T.B., Di Bernardo, M., Shoulson, R.L., Wai Chua, C., Kim, J.Y. Lankarani, A., Chakrapani, P., Syed, T., McKiernan, J.M., Solit, D.B., Shen, M.M., Al-Ahmadie, H., and Abate-Shen, C. (2021). Novel mouse models of bladder cancer identify a prognostic signature associated with risk of disease progression. Cancer Research. DOI: 10.1158/0008-5472.CAN-21-1254.
Papachristodoulou, A., Rodriguez-Calero, A., Panja, S., Margolskee, E., Virk, R. K., Milner, T. A., Pina Martina, L., Kim, J. Y., Di Bernardo, M., Williams, A. B., Maliza, E. A., Caputo, J. M., Haas, C., Wang, V., De Castro, G. J., Wenske, S., Hibshoosh, H., McKiernan, J. M., Shen, M. M., Rubin, M. A., Mitrofanova, A., Dutta, A., and Abate-Shen, C. (2021). NKX3.1 localization to mitochondria suppresses prostate cancer initiation. Cancer Discov. 2021 Sep;11(9):2316-2333. PMID: 33893149.
Arriaga, J. M., Panja, S., Alshalalfa, M., Zhao, J., Zou, M., Giacobbe, A., Madubata, C. J., Kim, J. Y., Rodriguez, A., Coleman, I., Virk, R., Hibshoosh, H., Ertunc, O., Oznek, B., Fountain, J., Karnes, R. J., Luo, J., Antonarakis, E. S., Nelson, P., Feng, F. Y., Rubin, M. A., De Marzo, A. M., Rabadan, R., Sims, P. A., Mitrofanova, A., and Abate-Shen, C.(2020). A MYC and RAS co-activation signature in localized prostate cancer drives bone metastasis and castration resistance. Nature Cancer. PMCID: PMC8171279.
Aytes, A., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J., Palomero, L., Farran-Matas, S., Rubin, M.A., Shen, M.M., Califano, C., and Abate-Shen, C. (2018). NSD2 is a conserved driver of metastatic prostate cancer progression. Nature Communications, 9:5201-5215. PMCID: PMC6281610.
Zou, M., Toivanen, R., Mitrofanova, A. Floch, N., Hayati, S., Sun, S., Le Magnen, C., Chester, D., Mostaghel, E.A., Califano A, Rubin, M.A., Shen, M.M.*, and Abate-Shen, C.* (2017) Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer. Cancer Discovery, 7: 736-749. (*co-corresponding) PMCID: PMC5501744.
Le Magnen, C., Virk, R.K, Dutta, A., Kim, J.Y., Panja, S., Lopez-Bujanda, Z.A., Califano, A., Drake, C.G., Mitrofanova, A., and Abate-Shen, C. (2018.) Cooperation of loss of NKX3.1 and inflammation in prostate cancer initiation. Disease Models and Mechanisms, Epub 2018/09/30. PMID: 30266798.
Dutta, A., Panja,S., Virk, R.K., Kim, J.Y., Zott, R., Cremers, S., Golombos, D. M., Liu, D., Mosquera, J.M., Mostaghel, E.A., Barbieri, C.E., Mitrofanova, A.M., and Abate-Shen, C. (2017) Co-clinical analysis of a genetically-engineered mouse model and human prostate cancer reveals significance of NKX3.1 expression for response to 5α-reductase inhibition. European Urology, 72: 499-506. PMCID: PMC5600823.
Owczarek, T. B., Kobayashi, T., Ramirez, R., Rong, L., Puzio-Kuter, A. M., Iyer, G., Teo, M. Y., Sánchez-Vega, F., Wang, J., Schultz, J., Zheng, T., Solit, D. B., Al-Ahmadie, H. A., and Abate-Shen, C. (2017) ARF confers a context-dependent response to chemotherapy in muscle invasive bladder cancer. Cancer Res. 77:1035-1046. PMCID: PMC5313321
Dutta, A., Le Magnen, C., Mitrofanova, A., Ouyang, X., Califano, A., and Abate-Shen, C. (2016) Identification of an NKX3.1-G9a-UTY transcriptional regulatory network that controls prostate differentiation. Science 352: 1576-1580. PMCID: PMC5507586
Selected Reviews and Commentaries
- Giacobbe, A. and Abate-Shen, C. (2021). Modeling metastasis in mice: a closer look. Trends in Cancer. DOI: https://doi.org/10.1016/j.trecan.2021.06.010.
- Arriaga, J.M. and Abate-Shen, C. (2018). Genetically-engineered mouse models of prostate cancer in the post-genomic era. Cold Spring Harb Perspect Med, in press. Epub 2018/04/18. PMID: 29661807.
- Le Magnen, C. Shen, MM, and Abate-Shen, C. (2018). Lineage plasticity in cancer progression and treatment. Annual Review of Cancer Biology. 2: 271-289. PMCID: PMC5942183.
- Le Magnen, C., Dutta, A., and Abate-Shen, C. (2016). Optimizing mouse models for precision cancer prevention. Nat. Rev. Cancer 16: 187-196. PMCID: PMC5517771
- Kobayashi, T., Owczarek, T.B., McKiernan, J.M., and Abate-Shen, C. (2015). Modeling bladder cancer in mice: opportunities and challenges. Nat. Rev. Cancer 15: 42-54. PMCID: PMC4386904.
- Shen, M.M., and Abate-Shen, C. (2010). Molecular genetics of prostate cancer: new prospects for old challenges.Genes Dev. 24:1967-2000. PMCID: PMC2939361.
- Abate-Shen, C., and Shen, M. (2000). Molecular genetics of prostate cancer. Genes Dev. 14:2410-2434. PMID: 11018010. PMID: 11018010.
Complete List of Published Work
https://www.ncbi.nlm.nih.gov/myncbi/cory.abate-shen.1/bibliography/public/